Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi

Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi

July 25, 2023 Editor 0

Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi

Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi

Cheech and Chong’s Cannabis Co., the renowned pioneers of the cannabis industry, and Southern Sky Brands, a leading provider of medical cannabis products, are excited to announce a strategic partnership aimed at expanding access to high-quality medical cannabis products for the patients of Mississippi.

“This partnership is all about the patients. We want to ensure that the people of Mississippi have access to safe, effective, and compassionate medical cannabis options,” said Tommy Chong, co-founder of Cheech and Chong’s Cannabis Co. “By combining our knowledge and resources with Southern Sky Brands, we can make a real difference in improving the lives of patients in need.”

Cheech Marin, co-founder of Cheech and Chong’s Cannabis Co. added, “We believe in the power of medical cannabis to provide relief and promote wellness. Through this partnership, we are dedicated to delivering innovative products and patient-centric care to the people of Mississippi. Together, we can break down barriers and reduce stigma surrounding medical cannabis.”

The partnership’s primary focus is to address the pressing need for medical cannabis in Mississippi, working closely with healthcare professionals, regulatory authorities, and local communities to ensure patients receive the best possible care. By leveraging the unique strengths of both organizations, Cheech and Chong’s Cannabis Co. and Southern Sky Brands aim to shape the medical cannabis landscape in the state and improve the lives of patients in need.

As part of this partnership, Southern Sky Brands, with their extensive experience in cannabis cultivation, production, and distribution, will bring their expertise and state-of-the-art cultivation facilities to ensure a steady supply of premium-quality medical cannabis products. They are dedicated to upholding the highest standards of quality and safety, ensuring that patients in Mississippi have access to exceptional medical cannabis options.

Both Cheech and Chong’s Cannabis Co. and Southern Sky Brands share a common vision of empowering patients and promoting wellness through the responsible use of medical cannabis. This partnership marks a significant step forward in achieving that goal as we collaborate to provide Mississippians with compassionate care, innovative products, and a patient-centric approach.

We look forward to the positive impact this partnership will have on patients’ lives in Mississippi, as well as the potential to serve as a model for responsible medical cannabis access in other regions. By combining our resources, knowledge, and passion for the industry, we are confident that Cheech and Chong’s Cannabis Co. and Southern Sky Brands will make a lasting difference in the lives of patients in need.

About Cheech and Chong’s Cannabis Co.:

Cheech and Chong’s Cannabis Co. is a renowned name in the cannabis industry, recognized for their pioneering contributions and advocacy for responsible cannabis use. With a rich history and deep-rooted knowledge of cannabis culture, Cheech and Chong’s Cannabis Co. is committed to providing high-quality cannabis products and promoting wellness for all.

cheechandchong.com

About Southern Sky Brands:

Southern Sky Brands is a farm-to-patient focused medical cannabis company. We bring modern, state-of-the-art indoor cultivation methods to natural plant medicine. Our baseline standard is a medical-grade approach to growth, cultivation, and processing. We hold ourselves to the highest standards and procedures to produce high-quality, consistent plant medicine for patients with debilitating conditions. We are proudly Mississippi made.

southernskybrands.com

Contact Information:

Brooke Mangum

CMO

[email protected]

Morgan Engle

Director of Technology & Marketing

[email protected]

Original Source:

Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi

The post Cheech and Chong’s Cannabis Co. and Southern Sky Brands Partner to Provide Medical Cannabis Access in Mississippi appeared first on AESTHETIC NEWS.

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

July 19, 2023 Editor 0

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s DiseaseNeurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease

Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.

Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.

“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”

Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience. 

The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.

Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.

Key findings from the TRAILBLAZER-ALZ 2 study include:

●   Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.

●   Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.

These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.

“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.

Contact Information:

Krista Clark

Marketing Director

[email protected]

7072529665

Original Source:

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

The post Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease appeared first on AESTHETIC NEWS.

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

July 19, 2023 Editor 0

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s DiseaseNeurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease

Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.

Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.

“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”

Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience. 

The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.

Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.

Key findings from the TRAILBLAZER-ALZ 2 study include:

●   Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.

●   Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.

These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.

“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.

Contact Information:

Krista Clark

Marketing Director

[email protected]

7072529665

Original Source:

Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease

The post Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease appeared first on AESTHETIC NEWS.

Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease Center

Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease Center

July 19, 2023 Editor 0

Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease Center

Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease CenterPanoramic Health, the Largest Physician-Led CKCC Participant, Drives Integrated, Value-Based Care to Patients With CKD-ESRD in South Texas Through Its Partnership With San Antonio Kidney Disease Center

The post Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease Center appeared first on AESTHETIC NEWS.

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers

July 19, 2023 Editor 0

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language BarriersAchieving the standard of care, no matter the language or disability.

Vidatak is proud to announce the latest feature, Talk-to-Translate, has just been added to VidaTalk to better ensure providers can deliver equitable care to patients with communication barriers and disabilities on a 24/7 basis.

VidaTalk is a first-in-kind, multilingual, point-of-care communication solution for patients with speech, hearing and language barriers. This customizable app for patients and providers includes picture-option communication selections that generate bilingual text and audio output when selections are made across 40 language profiles, relaxation videos, therapeutic restorative music, video and audio interpreter access, talk-to-text, and now, talk-to-translate. The new talk-to-translate feature released today ensures that even under the rarest circumstances, patients and providers will be able to understand one another.

Language barriers pose significant challenges in healthcare where effective and timely communication is vital. While in-person and remote video and telephonic interpreter services provide this essential service as the standard of care, they simply are not always feasible or available with every patient encounter, especially for languages spoken with lower frequency. 

With delayed or absent access to interpreters, providers find themselves unable to communicate with or understand their patients. This communication gap exposes patients to significant risk of harm, misdiagnosis, delayed diagnosis, and delayed or absent treatment. While for complex conversations, such as discharge instructions, Google Translate has been shown to be unreliable, in certain circumstances, it may be necessary.

“As VidaTalk continues to harness the technologies that drive equitable experiences for vulnerable patient populations, it is essential for hospitals to consider what their standard of care actually delivers with respect to a real-time multilingual experience and a human-centered approach to care.” – Dr. Patak, CEO of Vidatak

Vidatak’s Chief Experience Officer, Lisa Spencer, shares a personal experience she had with a loved one: “My family member could not communicate his needs and symptoms. It was frustrating and heartbreaking for everyone. I’m not alone. Every hospital is caring for patients with speech, hearing and language barriers. For patients that don’t speak the same language as their caregivers, using certified interpreters is the gold standard; but, when no one with language services is available, patients still need to communicate. That’s why I’m so excited that VidaTalk now has this new talk-to-translate feature. No one deserves to suffer or be in pain for hours, or even an entire weekend, simply because an interpreter can’t be reached.”

By ensuring that multilingual communication can occur in real time at the point of care, VidaTalk validates the highest standard of care, establishing a mechanism for effective communication for patients who have speech, hearing or language barriers. This vital connection can alleviate patient distress, enhance trust, and contribute to a more positive healthcare experience. When patients feel understood and supported, they are more likely to actively engage in their own healthcare journey, leading to better compliance, faster recovery, and enhanced overall well-being.

VidaTalk has revolutionized the healthcare experience for hospitalized patients who cannot speak, cannot hear, or have limited English proficiency. “As VidaTalk continues to harness the technologies that drive equitable experiences for vulnerable patient populations, it is essential for hospitals to consider what their standard of care actually delivers with respect to a real-time multilingual experience and a human-centered approach to care,” states Dr. Patak, CEO of Vidatak.

Contact Information:

Lance Patak

CEO

[email protected]

(323) 697-9906

Lisa Spencer

Chief Experience Officer

[email protected]

‭(425) 247-4007‬



Related Files
Adults with Communication Disabilities Experience Poorer Health and Healthcare Outcomes Compared to Persons Without Communicatio
Giving Voice- Nurse-Patient Communication in the Intensive Care Unit.pdf

Related Images

Original Source:

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers

The post VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers appeared first on AESTHETIC NEWS.